Products from Novo Nordisk
- Top pick1
#1· Editor's ChoiceEditor's ChoiceBest for CV RiskFDA-approved semaglutide for chronic weight management
- Average 15% weight loss in clinical trials (STEP 1)
- FDA-approved with extensive safety record
- Weekly dosing
FDA-approvedBrand-nameOnce-weekly injectionGLP-1 receptor agonistInsurance eligible - 2
Runner-upSemaglutide approved for type 2 diabetes
- Strong A1C reduction in T2D
- Often covered by insurance for diabetes indication
Off-label useOnce-weekly injectionGLP-1 receptor agonistInsurance eligible - 3
Also greatFirst FDA-approved oral semaglutide for weight loss (Jan 2026)
- First non-injection FDA-approved weight-loss GLP-1
- Same active ingredient as injection Wegovy with strong efficacy data
- Easier psychological adoption for needle-averse patients
FDA-approvedBrand-nameDaily oral tabletGLP-1 receptor agonistInsurance eligible - 4
Oral semaglutide for type 2 diabetes (FDA-approved 2019)
- First FDA-approved oral GLP-1 (2019) — long real-world safety record
- T2D indication = strong insurance coverage
- No injection
FDA-approvedBrand-nameDaily oral tabletGLP-1 receptor agonistInsurance eligible - 5
Daily liraglutide for weight loss
- Long FDA approval history (since 2014)
- Pediatric approval (age 12+)
FDA-approvedBrand-nameDaily injectionGLP-1 receptor agonist